Comparison of Influenza Vaccine Effectiveness Estimates Using Test-Negative Prospective Enrollment and Electronic Health Record Data, United States, 2024--2025
Price, A. M.; McLean, C.; Cleary, S.; Leis, A. M.; Vaughn, I. A.; House, S.; Ellsworth, S.; Moehling Geffel, K.; Taylor, L. H.; Gaglani, M.; Murthy, K.; Saade, E. A.; Ladikos, C.; Murugan, V.; Kramer, J. L.; Williamson, B. D.; Kiniry, E.; Walter, E. B.; Bontrager, N. A.; Ellington, S.; Flannery, B. M.; Chung, J.; US Flu VE Network Investigators,
Show abstract
Background: Influenza vaccine effectiveness (VE) is assessed annually through prospective enrollment of patients presenting with acute respiratory symptoms in a test-negative study design. Influenza VE has also been estimated from electronic health record (EHR) databases by linking medical diagnoses, laboratory test results, and patient influenza vaccination. There are limited data on agreement between influenza VE estimates from prospective enrollment versus EHR databases. Methods: The US Influenza Vaccine Effectiveness Network prospectively enrolled outpatients meeting clinical screening criteria and collected respiratory specimens to determine influenza virus infection. Seven study sites also identified EHR databases that included diagnostic codes for outpatient encounters associated with medically attended acute respiratory illness (MAARI), clinical respiratory virus testing, and influenza vaccination status. Effectiveness of influenza vaccination against laboratory-confirmed influenza was estimated from both data sources using logistic regression models including patient age, study site, and month of illness as 100(%) x (1 - adjusted odds ratio), comparing influenza vaccination among laboratory-confirmed influenza-positive patients versus laboratory-confirmed influenza-negative patients. Results: From October 2024--April 2025, 2,016 (30%) of 6,793 prospectively enrolled patients and 75,885 (24%) of 282,444 EHR MAARI encounters had laboratory-confirmed influenza virus infection. Effectiveness of vaccination against laboratory-confirmed influenza was 36% (95% confidence interval [CI]: 26-44) among prospectively enrolled patients and 38% (95% CI: 36-39) among EHR MAARI encounters. Comparing influenza VE estimates from the two data sources, confidence intervals overlapped for all age groups except for adults aged [≥]65 years: -3% (95% CI: -53-30) among prospective enrollment versus 35% (95% CI: 32-39) VE from EHR MAARI encounters. Conclusion: Overall, influenza VE estimates from retrospective EHR data were similar to VE estimates using the test-negative design with prospective enrollment. The age group-specific differences in estimated VE observed in US adults aged [≥]65 years compared with younger age groups merit further investigation.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Using Capture-Recapture Methods to Estimate Influenza Hospitalization Incidence Rates 95%
- The Oregon Child Absenteeism Due to Respiratory Disease Study (ORCHARDS): Rationale, Objectives, and Design 94%
- mRNA COVID-19 vaccine effectiveness against SARS-CoV-2 infection in a prospective community cohort, rural Wisconsin, November 2020-December 2021 94%
Similar papers in this journal
- Clinical symptoms among ambulatory patients tested for SARS-CoV-2 94%
- Effectiveness of the 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine (mRNA-1273.815) in preventing COVID-19-related hospitalizations and medical encounters among adults in the United States: An interim analysis 92%
- Estimates of presumed population immunity to SARS-CoV-2 by state in the United States, August 2021 92%
Similar papers in this journal
- Agreement between state registry, health record, and self-report of influenza vaccination 95%
- Safety Monitoring of Health Outcomes following Influenza Vaccination during the 2023-2024 Season among U.S. Medicare Beneficiaries Aged 65 Years and Older 94%
- Receipt of COVID-19 and seasonal influenza vaccines in California (USA) during the 2021-2022 influenza season 94%
Similar papers in this journal
- Relative contribution of COVID-19 vaccination and SARS-CoV-2 infection to population-level seroprevalence of SARS-CoV-2 spike antibodies in a large integrated health system 94%
- Estimating the number of symptomatic SARS-CoV-2 infections among vaccinated individuals in the United States—January–April, 2021 93%
- Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review 92%
Similar papers in this journal
- Association of E484K and L452R spike protein mutations with SARS-CoV-2 infection in vaccinated persons---Maryland, January – May 2021 93%
- Associations between SARS-CoV-2 variants and risk of COVID-19 hospitalization among confirmed cases in Washington State: a retrospective cohort study 93%
- Effectiveness of Influenza Vaccines in the HIVE household cohort over 8 years: is there evidence of indirect protection? 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.